Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  TEL AVIV STOCK EXCHANGE  >  Anchiano Therapeutics Ltd       IL0011267882

ANCHIANO THERAPEUTICS LTD

SummaryChartsNewsCompany 
News SummaryMost relevantAll newsOfficial PublicationsSector news

Anchiano Therapeutics : Announces Pricing of $30.5 Million Initial Public Offering

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/12/2019 | 09:16am EDT

CAMBRIDGE, Mass., Feb. 12, 2019 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (Nasdaq and TASE: ANCN) (“Anchiano”) today announced that it has priced its initial public offering of 2,652,174 of its American Depositary Shares (“ADSs”), each representing five ordinary shares of Anchiano, at $11.50 per ADS, less underwriting discounts and commissions. The ADSs are expected to begin trading on the Nasdaq Capital Market (“Nasdaq”) under the symbol “ANCN” on February 12, 2019, and the offering is expected to close on or about February 14, 2019.

The underwriters have been granted a 30-day option to purchase up to an additional 397,826 ADSs offered by Anchiano to cover over-allotments, if any.

In the offering, Oppenheimer & Co. Inc. is acting as the sole book-running manager, Ladenburg Thalmann is acting as lead manager and LifeSci Capital LLC is acting as co-manager.

The offering is being made only by means of a prospectus, copies of which can be obtained  from Oppenheimer & Co. Inc., Attention: Syndicate Prospectus Department, 85 Broad St., 26th Floor, New York, NY 10004, by telephone at (212) 667-8055 or by email at EquityProspectus@opco.com.

A registration statement relating to these securities was filed with and declared effective by the U.S. Securities and Exchange Commission on February 11, 2019. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to their registration or qualification under the securities laws of any such state or jurisdiction.

About Anchiano
Anchiano is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat cancer, with offices in Cambridge, MA, and Jerusalem, Israel. Anchiano’s most advanced product candidate, inodiftagene vixteplasmid, is in development as a treatment for non-muscle-invasive bladder cancer. For more information on Anchiano, please visit www.anchiano.com.

Forward Looking Statements
This press release contains “forward-looking statements” that are subject to risks and uncertainties. These forward-looking statements are based on information Anchiano has when those statements are made or its management’s good faith belief as of that time with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements.

Company Contact:

Frank Haluska, M.D., Ph.D.
President and Chief Executive Officer
info@anchiano.com

Investor Contact:
Ashley R. Robinson
Managing Director
LifeSci Advisors, LLC
617-535-7742
arr@lifesciadvisors.com

Anchiano_high resolution.jpg

Source: Anchiano Therapeutics

2019 GlobeNewswire, Inc., source Press Releases

Stocks mentioned in the article
ChangeLast1st jan.
ANCO THER 0.00%End-of-day quote.0.00%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ANCHIANO THERAPEUTICS LTD
02/12ANCHIANO THERAPEUTICS : Announces Pricing of $30.5 Million Initial Public Offeri..
AQ
01/08ANCHIANO THERAPEUTICS : Announces Filing of F-1 Registration Statement for U.S. ..
AQ
01/07Anchiano Therapeutics Announces Filing of F-1 Registration Statement for U.S...
GL
2018ANCHIANO THERAPEUTICS : Announces Initiation of Its Pivotal Codex Study of Inodi..
AQ
2018ANCHIANO THERAPEUTICS : Announces Initiation of Its Pivotal Codex Study of Inodi..
AQ
2018ANCHIANO THERAPEUTICS : Announces Appointment of Dr. David Kerstein as New Chief..
AQ
2018Anchiano Therapeutics Announces Appointment of Dr. David Kerstein as New Chie..
GL
2018Anchiano Therapeutics Reports Third Quarter 2018 Financial and Operational Re..
GL
2018ANCHIANO THERAPEUTICS : announces appointment of new Chairman and Director
AQ
2018Anchiano Therapeutics Appoints Dr. Stephen Hoffman and Robert Connelly to Its..
GL
More news
Chart ANCHIANO THERAPEUTICS LTD
Duration : Period :
Anchiano Therapeutics Ltd Technical Analysis Chart | MarketScreener
Full-screen chart
Managers
NameTitle
Frank G. Haluska President & Chief Executive Officer
Stephen J. Hoffman Chairman
Jonathan Burgin Chief Financial & Operating Officer
Sean Daly Vice President-Clinical Operations
Michal Gilon Ohev Zion Vice President-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
ANCHIANO THERAPEUTICS LTD-46.08%0
GILEAD SCIENCES0.64%80 255
VERTEX PHARMACEUTICALS1.48%42 991
REGENERON PHARMACEUTICALS-10.75%35 789
GENMAB5.11%10 418
SAREPTA THERAPEUTICS INC6.88%8 594